8 Pulmonology Headlines you Missed in Q2 2026

Q2 2026 was anchored by the American Thoracic Society (ATS) 2026 International Conference in May and capped by expert coverage from the Association of Pulmonary Advanced Practice Providers (APAPP) National Conference in June. The quarter's defining readout came from the phase 3 TETON-1 trial, in which nebulized treprostinil demonstrated unprecedented efficacy across multiple endpoints in IPF — including the first statistically significant DLCO improvement in any phase 3 IPF trial and a regulatory submission planned for summer 2026. Across obstructive and vascular pulmonary disease, ralinepag's 55% PAH worsening reduction in ADVANCE OUTCOMES, tozorakimab's third consecutive positive phase 3 COPD exacerbation readout in MIRANDA, and the BGF triple inhaler's long-awaited approval for patients aged 12 and older rounded out a quarter defined by late-stage clinical momentum.